cardiovascular system
|
• angiotensin II infused mutants exhibit a greater disruption of the medial elastic lamellae and fibrillar structures in the abdominal aortic walls than in single Timp3 homozygotes
|
|
• angiotensin II infused mutants exhibit a greater disruption of the medial elastic lamellae and fibrillar structures in the abdominal aortic walls than in single Timp3 homozygotes
|
|
• 75% of mutants develop abdominal aortic aneurysm with greater than 50% aortic dilation in the suprarenal region after 4 weeks of angiotensin II infusion
• survival is compromised more than in single Timp3 homozygotes after angiotensin II infusion due to aortic rupture, with mice showing around 70% survival 28 days after infusion
• treatment with a broad spectrum protease inhibitor, PD166793, during the course of angiotensin II infusion blocks abdominal aortic aneurysm development
|
|
• mutants treated with angiotensin II exhibit heightened inflammation in the abdominal aorta, with enhanced infiltration of neutrophils and macrophages
|
immune system
|
• mutants treated with angiotensin II exhibit heightened inflammation in the abdominal aorta, with enhanced infiltration of neutrophils and macrophages
|
mortality/aging
|
• survival is compromised more than in single Timp3 homozygotes after angiotensin II infusion due to aortic rupture, with mice showing around 70% survival 28 days after infusion
|